INCY INCYTE CORP
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 879169 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.9%
TTM net income YoY-66.1%
TTM EPS YoY-66.8%
Revenue 3-yr CAGR18.5%
Net income 3-yr CAGR-1.7%
Margins
Gross margin92.7%
Operating margin10.4%
Net margin6.7%
FCF margin—
EBITDA margin12.1%
Returns
ROE7.8%
ROA5.9%
ROIC (approx.)13.9%
Asset turnover0.88x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.84x
Interest coverage267.97x
Cash quality & payout
Operating cash flow / net income1.85x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Cost of revenue | $372.13M | $312.07M | $254.99M | $207.00M | $150.99M |
| Gross profit | $4.77B | $3.93B | $3.44B | $3.19B | $2.84B |
| R&D expense | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B |
| SG&A expense | $1.38B | $1.24B | $1.16B | $1.00B | $739.56M |
| Operating income | $1.51B | $61.37M | $620.52M | $579.44M | $585.78M |
| Interest expense | $2.43M | $2.28M | $2.55M | $2.67M | $1.91M |
| Pretax income | $1.66B | $316.63M | $834.22M | $529.12M | $570.44M |
| Income tax | $377.80M | $284.01M | $236.62M | $188.46M | -$378.14M |
| Net income | $1.29B | $32.62M | $597.60M | $340.66M | $948.58M |
| EBITDA | $1.61B | $150.61M | $703.18M | $647.29M | $643.62M |
| EPS (basic) | 6.59 | 0.16 | 2.67 | 1.53 | 4.30 |
| EPS (diluted) | 6.41 | 0.15 | 2.65 | 1.52 | 4.27 |
| Weighted avg. shares (diluted) | 200.70M | 210.53M | 225.93M | 223.96M | 222.07M |
| Balance sheet | |||||
| Cash & equivalents | $3.10B | $1.69B | $3.22B | $2.95B | $2.06B |
| Short-term investments | — | — | $442.67M | $287.54M | $290.75M |
| Inventory | $101.06M | $58.87M | $62.97M | $41.99M | $27.90M |
| Current assets | $5.02B | $3.24B | $4.65B | $4.09B | $3.12B |
| PP&E, net | $730.88M | $763.41M | $751.51M | $739.31M | $723.92M |
| Goodwill | $133.00M | $155.59M | $155.59M | $155.59M | $155.59M |
| Total assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B |
| Current liabilities | $1.52B | $1.64B | $1.24B | $1.16B | $854.31M |
| Total liabilities | $1.79B | $2.00B | $1.59B | $1.47B | $1.16B |
| Shareholders' equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B |
| Shares outstanding | 198.46M | 193.43M | 224.29M | 222.75M | 221.08M |
| Cash flow statement | |||||
| Operating cash flow | $1.41B | $335.34M | $496.49M | $969.94M | $749.49M |
| Capital expenditure | — | — | — | $77.83M | $181.01M |
| Free cash flow | — | — | — | $892.11M | $568.48M |
| Investing cash flow | -$102.61M | $157.52M | -$207.68M | -$78.54M | -$207.70M |
| Financing cash flow | $101.04M | -$2.02B | -$20.03M | -$794,000 | $6.18M |
| Depreciation & amortization | $93.29M | $89.25M | $82.66M | $67.86M | $57.84M |
| Stock-based compensation | $249.35M | $266.06M | $215.89M | $188.42M | $183.01M |
| Share buybacks | $0 | $2.00B | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.